Obalon Therapeutics, Inc. provided revenue guidance for the fourth quarter and year ended December 31, 2017. For the quarter, the company expected revenue of approximately $3.9 million an estimated increase of approximately 400% over the fourth quarter of 2016. For the full year 2017, total preliminary, revenue is expected to be $10.1 million, an estimated increase of approximately 200% over 2016.